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ABSTRACT
Objective: To evaluate the long-term safety and efficacy
of adalimumab in patients with ankylosing spondylitis (AS)
and total spinal ankylosis (TSA).
Design: Patients (n=315) with active AS were
randomised in a 2:1 ratio to receive adalimumab 40 mg
every other week or placebo for 24 weeks followed by
open-label adalimumab for up to 5 years. Two-year
efficacy and safety data for 11 patients with investigator-
defined TSA were evaluated. The primary end point was
the ASsessment in AS International Working Group
criteria for 20% improvement (ASAS20) at Week 12. On
or after Week 12, ASAS20 non-responders could switch
to open-label adalimumab. Other efficacy measurements
included ASAS40, ASAS 5/6, ASAS partial remission, and
50% improvement in the Bath AS Disease Activity Index
(BASDAI 50).
Results: 6 of 11 TSA patients were randomised to
adalimumab and 5 to placebo. At Week 12, 50% of the
adalimumab-treated patients achieved an ASAS20
response and 33% achieved an ASAS40, ASAS 5/6 and
BASDAI 50. No placebo-treated patients achieved any
response criteria at Week 12. 4 placebo- and 2
adalimumab-treated patients switched to open-label
adalimumab before Week 24. After 1 year of adalimumab
treatment, 8 of 11 patients achieved an ASAS20
response. After 2 years, 6 of the remaining 8 patients
with TSA reported an ASAS20 response. There were no
serious adverse events or adverse event-related study
discontinuations.
Conclusion: In patients with TSA, adalimumab treatment
resulted in rapid and clinically significant improvement in the
signs and symptoms of active disease. Adalimumab
effectiveness and safety were sustained for at least 2 years.
Trial registration number: NCT00085644.
Ankylosing spondylitis (AS) typically strikes young
adults, with the burden of disease attributable
primarily to the resulting functional disability.
1
The disease course varies widely. Some patients
experience sacroiliitis alone, while others experi-
ence rapid progression to end-stage fusion of the
spine, or total spinal ankylosis (TSA).
2 Patients
who develop TSA (ie, bamboo spine) experience
significantly more functional impairment and are
less likely to be employed compared with other
patients with AS.
3 In addition to substantial
functional disability, patients with TSA may
experience a more debilitating disease course. The
fragility of the rigid spinal column increases the
risk of spinal fractures and possible neurological
sequelae, and spinal deformities may contribute to
respiratory and other difficulties.
1 In contrast to
pre-existing concepts, patients with TSA may
continue to have signs and symptoms of active
AS, which are insufficiently responsive to non-
steroidal anti-inflammatory drugs (NSAIDs).
Patients with TSA are typically excluded from
participation in randomised controlled trials of
therapeutic agents for AS. For example, the
randomised controlled trials of the tumour necrosis
factor (TNF) antagonists etanercept and infliximab
have excluded AS patients with TSA.
45 The
Adalimumab Trial Evaluating Long-term Efficacy
and Safety for AS (ATLAS) was the first large
randomised controlled trial of a TNF antagonist in
patients with active AS that permitted patients
diagnosed with TSA.
6 Our objective was to
evaluate the long-term safety and efficacy of
adalimumab in patients with TSA who had
participated in ATLAS.
PATIENTS AND METHODS
Patients
ATLAS has been described in the published report
of the 24-week, double-blind results.
6 Adults with
AS based on the modified New York criteria
7 who
had active disease were recruited for the study.
ATLAS was designed with an a priori limit on
enrolment of patients with TSA of 10%. A
diagnosis of TSA was based on the investigators’
assessments of lateral radiographs of the cervical
and lumbar spine and lateral views of chest
radiographs. All enrolled patients had an inade-
quate response or intolerance of one or more
NSAIDs, as defined by the investigators. Also,
patients who had failed therapy with one or more
disease-modifying antirheumatic drugs were
allowed to participate.
Each of the 43 study centres obtained indepen-
dent ethics committee approval, and ATLAS was
conducted in accordance with the Declaration of
Helsinki. Compliance with local laws and customs
was assured by investigators at the 43 centres in
Europe (Belgium, France, Germany, Italy, The
Netherlands, Spain, Sweden, and the United
Kingdom) and the USA. Written informed consent
was obtained from each patient before any study-
related procedures were initiated.
Study design
Patients were randomised to receive adalimumab
40 mg every other week (eow) or matching placebo
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syringes containing either adalimumab 40 mg or placebo for
subcutaneous injection (Abbott Laboratories, Abbott Park, IL).
The primary efficacy end point was the percentage of patients
at Week 12 who achieved a 20% response according to the
ASsessment in AS International Working Group criteria for
improvement (ASAS20).
8 Patients who did not achieve an
ASAS20 response at Weeks 12, 16 or 20 were eligible to receive
early escape, open-label treatment with adalimumab 40 mg
eow. After the Week 24 visit, all patients were eligible to receive
open-label adalimumab treatment in the ongoing study for up
to 5 years. Data for patients with TSA who received
adalimumab (blinded or open-label) for up to 2 years are
presented here.
Efficacy assessments
Additional efficacy assessments included the following criteria:
ASAS40 response (defined as improvement of at least 40% and
absolute improvement of at least two units (on a 0–10-point
scale) compared with baseline in at least three of the four
ASAS20 criteria domains with no deterioration in the remaining
domain); ASAS 5/6 response (defined as at least 20% improve-
ment in five of six of the following domains: the four domains
of the ASAS20 criteria plus spinal mobility as measured by the
3-point Bath AS Metrology Index (BASMI)
9 and an acute-phase
reactant as measured by C-reactive protein concentration), and
ASAS partial-remission response (defined as a value of ,2o na
0–10-point scale in each of the four ASAS20 domains).
10 Mean
values for each of the four ASAS20 criteria domains were also
evaluated: patient’s global assessment of disease activity, total
back pain, function according to the Bath AS Functional Index
(BASFI),
11 and inflammation based on the mean of questions 5
and 6 of the Bath AS Disease Activity Index (BASDAI)
pertaining to morning stiffness severity and duration.
12 An
improvement of at least 50% in the BASDAI score (BASDAI 50),
which measures the severity of fatigue, spinal and peripheral
joint pain, local tenderness, and morning stiffness (both
qualitative and quantitative) using a 0–10 cm visual analogue
scale (VAS), was also noted for each patient.
Safety assessments
Safety assessments were completed and adverse events were
collected throughout the double-blind and open-label extension
study periods. Flares of extra-articular disease manifestations
were not prospectively or systematically collected during the
study.
Statistical analyses
Because of the small number of patients with TSA, there were no
statistical comparisons made between treatment groups. Both
efficacy and safety results are summarised descriptively. Observed
data at Years 1 and 2 are based on total duration of adalimumab
exposure (ie, double-blind and open-label treatment).
RESULTS
Baseline characteristics and study disposition
Of the 315 patients enrolled in ATLAS, 11 had investigator-
diagnosed TSA; 5 were randomised to receive placebo and 6
were randomised to receive adalimumab 40 mg eow. Baseline
demographics and disease activity for these 11 patients are
summarised in table 1. After the Week 12 visit, 4 placebo-
treated patients and 2 adalimumab-treated patients entered
early escape, open-label treatment with adalimumab 40 mg
eow. All 11 patients with TSA received 1 year of adalimumab
treatment; 8 of these patients received at least 2 years of
adalimumab treatment.
Efficacy
The ASAS20, ASAS40, ASAS 5/6, and BASDAI 50 responses for
each patient with TSA are shown in table 2. At Week 12, all
placebo-treated patients had no response based on any of these
response criteria, whereas 50% of the six adalimumab-treated
patients attained an ASAS20 response and 33% achieved an
ASAS40, ASAS 5/6, and BASDAI 50 response. At Week 24, all
four of the patients who remained on blinded adalimumab
therapy had an ASAS20 response, two had an ASAS40 response,
and three had an ASAS 5/6 and BASDAI 50 response. The one
patient who continued to receive placebo at Week 24 did not
achieve any of the response criteria. None of the patients with
TSA in either treatment group achieved ASAS partial remission
at Weeks 12 or 24.
Of the four placebo-treated patients who switched to early
escape, open-label adalimumab therapy on or after Week 12,
three had an ASAS20 response and two had ASAS40, ASAS 5/6,
and BASDAI 50 responses by Week 24.
After 1 year of adalimumab exposure, 8 of the 11 patients
with TSA had an ASAS20 response, and 1 patient had ASAS-
defined partial remission (table 3). After 2 years of exposure,
there was continued clinical benefit from adalimumab therapy.
The mean values for each of the four ASAS20 domains after 2
years of adalimumab exposure were: 3.5 for patient’s global
assessment; 3.1 for total back pain; 4.9 for function (BASFI);
and 3.8 for inflammation (items 5 and 6 of the BASDAI).
After receiving adalimumab for 1 year, only one patient with
TSA achieved ASAS partial remission; no patients were in partial
remission after 2 years of exposure. This patient was the only one
who had a value of ,2 units (0–10 cm VAS) for function (BASFI).
However, the following numbers of patients had values ,2u n i t s
for the other ASAS domains after 1 year and 2 years of
adalimumab treatment, respectively: patient’s global assessment,
3 and 2; total back pain, 4 and 4; and inflammation, 4 and 3.
Table 1 Baseline demographic and clinical characteristics of the
patients with total spinal ankylosis, by treatment group
Variable Placebo (n=5)
Adalimumab 40 mg
eow (n=6)
Male, n (%) 5 (100) 4 (66.7)
White, n (%) 5 (100) 6 (100)
Age (years), mean (SD) 50.2 (7.8) 54.2 (5.9)
Disease duration (years), mean (SD) 16.6 (5.9) 25.6 (7.4)
HLA-B27 positive, n (%) 5 (100) 4 (66.7)
DMARD use prior to or at baseline, n (%) 5 (100) 4 (66.7)
Concomitant NSAID use, n (%) 4 (80.0) 5 (83.3)
Concomitant corticosteroid use, n (%) 0 (0) 0 (0)
Patient’s global assessment of disease
activity (cm), mean (SD)
6.2 (1.9) 8.7 (1.0)
Total back pain (cm), mean (SD) 5.1 (3.4) 6.6 (3.4)
Inflammation* (cm), mean (SD) 7.8 (1.7) 8.0 (0.8)
BASFI (cm), mean (SD) 7.5 (1.3) 8.0 (1.1)
BA(SD)AI (cm), mean (SD) 6.1 (1.6) 7.6 (1.0)
CRP (mg/dL), mean (SD) 2.9 (2.9) 3.3 (2.6)
BASMI (0–10), mean (SD) 6.4 (1.3) 7.8 (0.8)
BA(SD)AI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath
Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing Spondylitis
Metrology Index; CRP, C-reactive protein; DMARD, disease-modifying anti-rheumatic
drug; eow, every other week; NSAID, non-steroidal anti-inflammatory drug.
*Mean of questions 5 and 6 of the BA(SD)AI.
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measured by the BASMI. The observed mean changes in the
BASMI for the adalimumab and placebo groups were 0.2 and 0.0
at Week 12 and 20.5 and 1.0 at Week 24, respectively. After 1
year of adalimumab treatment, the mean change in the BASMI
was 20.6, and after 2 years, 20.8.
Braun and colleagues
2 published a radiographic staging system
for patients with AS. Stage V indicates widespread spinal
ankylosis (ie, bamboo spine), defined as >80% fusion of >20
vertebrae. Using these staging criteria retrospectively, 8 of the
11 patients had Stage V ankylosis (4 in the placebo group and 4
in the adalimumab group). The remaining 3 patients had Stage
IV radiographic changes, defined as radiographic evidence of
spinal involvement in .2 segments (13–19 vertebrae, 50%–
,80% of the spine). A post hoc analysis of these 8 Stage V
patients revealed a similar response pattern compared with the
11 patients with investigator-defined TSA (tables 2 and 3).
Safety
Complete safety data for all patients who participated in the
randomised, controlled portion of ATLAS have been reported.
6
All 11 patients reported at least one adverse event during the
controlled or open-label periods, but none were serious and
none led to discontinuation of study drug. There were no cases
of opportunistic infections, tuberculosis, malignancies, conges-
tive heart failure, demyelinating disorders, or lupus-like syn-
dromes, and there were no deaths.
DISCUSSION
Adalimumab therapy was associated with rapid and clinically
significant improvement in the signs and symptoms of active
AS in patients with TSA. In this small subgroup of patients
with AS, it is remarkable that at Week 12, the time point for
measurement of the primary efficacy end point, there was no
placebo response based on either ASAS or BASDAI response
criteria. The efficacy of adalimumab in patients with TSA was
maintained through 2 years of treatment. No significant safety
issues were observed in these patients.
The percentage of patients with TSA who experienced
responses to adalimumab was similar to that reported for the
overall study population of patients with active AS,
61 3except
for ASAS-defined partial remission. ASAS-defined partial remis-
sion was achieved by only one patient with TSA (Stage V) after
1 year of adalimumab exposure. Although some patients had
scores of ,2 for one or more of the ASAS domains, only one
patient was able to achieve this level for function (BASFI). In
these patients who had a significant irreversible component of
their disease status, certain response criteria may not appro-
priately reflect improvement in the reversible signs and
symptoms of AS.
These results are novel and clinically relevant because ATLAS
is the first and only randomised, controlled trial of a TNF
antagonist to include patients with TSA.
45These patients have
been excluded from participation in most clinical drug trials
because it was likely assumed that they would experience
minimal treatment benefit. However, this study demonstrated
1) that patients with TSA have evidence of active inflammatory
disease; and 2) that the symptoms of active disease in these
patients, including pain, functional impairment, and morning
stiffness, can be substantially improved with adalimumab
treatment. The overall pattern of response was similar when
the results were analysed for patients who met specific
radiographic staging criteria for TSA. Of particular clinical
importance was the finding that patients with TSA who
received long-term treatment with adalimumab (up to 2 years)
have a sustained clinical response over time.
Table 2 Efficacy results for patients with investigator-defined total spinal ankylosis or Stage V radiographic
criteria during the 24-week, double-blind period
Treatment
Entered
early
escape
therapy
Week 12 response Week 24 response
ASAS20 ASAS40 ASAS 5/6 BASDAI 50 ASAS20 ASAS40 ASAS 5/6 BASDAI 50
ADA* No !!! ! ! !— !
ADA No ! —— — ! — ! —
ADA No !!! — !! ! !
ADA* No — — — !! — !!
ADA* Yes — — — — 0 0 0 0
ADA* Yes — — — — 0 0 0 0
PBO* No — — — — — — — —
PBO Yes — — — — + 00 0
PBO* Yes — — — — ++ + +
PBO* Yes — — — — 0 0 0 0
PBO* Yes — — — — ++ + +
ADA, adalimumab; ASAS, ASsessment in Ankylosing Spondylitis International Working Group criteria for improvement; BASDAI,
Bath Ankylosing Spondylitis Disease Activity Index; PBO, placebo; !, Responder on blinded therapy; —, non-responder on blinded
therapy; +, responder on early escape, open-label adalimumab; 0, non-responder on early escape, open-label adalimumab.
*Patients fulfilling Stage V radiographic criteria for TSA.
Table 3 Long-term efficacy results for patients with investigator-
defined total spinal ankylosis or Stage V radiographic criteria*
Response variable
Investigator-defined TSA Stage V TSA
Total duration of
adalimumab exposure
Total duration of
adalimumab exposure
1 year
(n=11), (%)
2 years
(n=8), (%)
1 year
(n=8), (%)
2 years
(n=5), (%)
ASAS20 72.7 75.0 62.5 60.0
ASAS40 36.4 62.5 37.5 40.0
ASAS 5/6 54.5 37.5 37.5 20.0
ASAS partial remission 9.1 0 12.5 0
BASDAI 50 45.5 62.5 50.0 60.0
ASAS, ASsessment in Ankylosing Spondylitis International Working Group criteria for
improvement; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; TSA, total
spinal ankylosis.
*All data are based on observed efficacy analyses.
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result in rapid and sustained improvement in the signs and
symptoms of active AS. Longer-term observations of these
patients from the ATLAS trial will provide further insight on
the potential benefit of anti-TNF therapy in this subgroup of
patients with AS.
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